-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to information from the National Medical Insurance Bureau, the national medical insurance negotiations will be launched in early November
.
With the launch of a new round of medical insurance negotiations, which blockbuster new drugs will get tickets to the medical insurance catalogue has attracted much attention in the industry
.
There are a huge number of cancer patients in China, and because such drugs are often expensive, anti-tumor drugs are the focus in each round of medical insurance negotiations
.
It is understood that this national medical insurance negotiation will have more oncology innovative drugs, such as PD-1 monoclonal antibody, BTK inhibitors, PARP inhibitors, ADC drugs and so on
.
According to the list of drugs reviewed in the preliminary form, a total of 15 domestically-made innovative drugs participated in the national talks for the first time, including Ensatinib from Betta Pharmaceuticals, Obutinib from Nuocheng Jianhua, and Imitavir from Dongyang Sunshine
.
These drugs are all new drugs approved for marketing within the past three years, and 9 drugs are new drugs that have been marketed this year
.
Among these 15 domestically-made innovative drugs, there is no shortage of heavy CAR-T products, that is, 1.
2 million doses of anticancer drug-Achilles
.
It is understood that Akilun Race was introduced by Fosun Kate, and the cell product was approved on June 23, 2021 for the treatment of R/R LBCL adult patients after second-line or above systemic treatment, and officially landed in China
.
As the first approved CD19 CAR-T cell therapy drug in China, the approval of Akirensai opened a new chapter in the treatment of patients with relapsed and refractory large B-cell lymphoma after systemic treatment in China
.
However, the product needs to be customized and the cost is very expensive.
The current price is as high as 1.
2 million yuan per bag, and the patient only needs one infusion to achieve complete relief
.
According to the industry, in the previous rounds of medical insurance negotiations, many new drugs including PD-1 products have been significantly reduced in price after entering medical insurance.
For example, Cinda Bio's Sintilimab injection entered the 2019 medical insurance through a 63% price reduction, and the annual treatment cost Reduced to less than 100,000 yuan; in the 2020 medical insurance negotiations, BeiGene’s tislelizumab, Junshi Bio’s treprilizumab, and Hengrui Medicine’s carrelizumab are three domestically produced PD- 1 Products are also included in the medical insurance catalog
.
It is reported that after the three products enter the medical insurance, the annual treatment cost may be between 54,000 yuan and 80,000 yuan.
.
Judging from the degree of inclusion of oncology drugs in the previous rounds of medical insurance negotiations, it is expected that Akirensai will also have a good result in this medical insurance negotiation
.
However, some analysts believe that the possibility of Akirensai entering the medical insurance catalog is relatively small, and it is unrealistic for high-value drugs of up to one million to be included in the medical insurance
.
Fosun Kate staff also revealed to the media that the company is actively preparing for negotiations.
It is expected that negotiations will be difficult, but they will try hard
.
In the interpretation of the "Work Plan for Adjusting the National Medical Insurance Drug List in 2021", the National Medical Insurance Administration emphasized: "China is still a developing country, and the financing of basic medical insurance is very limited.
In 2020, the per capita financing of resident medical insurance is only about 800 yuan, of which one-third Second, it also comes from financial subsidies.
Therefore, we must firmly grasp the system positioning of "guarantee basics", focusing on including drugs with high clinical value, reasonable prices, and meeting basic medical needs into the catalog
.
In this year's adjustments, we will continue to strictly grasp Regarding standards and conditions, the society and reporting companies are also requested to maintain reasonable expectations
.
" According to the "Work Plan", if the negotiation goes smoothly, this catalog adjustment will be completed by the end of this year, and we will strive to start implementation in January 2022
.
It remains to be seen what the outcome of the national talks will be
.
.
With the launch of a new round of medical insurance negotiations, which blockbuster new drugs will get tickets to the medical insurance catalogue has attracted much attention in the industry
.
There are a huge number of cancer patients in China, and because such drugs are often expensive, anti-tumor drugs are the focus in each round of medical insurance negotiations
.
It is understood that this national medical insurance negotiation will have more oncology innovative drugs, such as PD-1 monoclonal antibody, BTK inhibitors, PARP inhibitors, ADC drugs and so on
.
According to the list of drugs reviewed in the preliminary form, a total of 15 domestically-made innovative drugs participated in the national talks for the first time, including Ensatinib from Betta Pharmaceuticals, Obutinib from Nuocheng Jianhua, and Imitavir from Dongyang Sunshine
.
These drugs are all new drugs approved for marketing within the past three years, and 9 drugs are new drugs that have been marketed this year
.
Among these 15 domestically-made innovative drugs, there is no shortage of heavy CAR-T products, that is, 1.
2 million doses of anticancer drug-Achilles
.
It is understood that Akilun Race was introduced by Fosun Kate, and the cell product was approved on June 23, 2021 for the treatment of R/R LBCL adult patients after second-line or above systemic treatment, and officially landed in China
.
As the first approved CD19 CAR-T cell therapy drug in China, the approval of Akirensai opened a new chapter in the treatment of patients with relapsed and refractory large B-cell lymphoma after systemic treatment in China
.
However, the product needs to be customized and the cost is very expensive.
The current price is as high as 1.
2 million yuan per bag, and the patient only needs one infusion to achieve complete relief
.
According to the industry, in the previous rounds of medical insurance negotiations, many new drugs including PD-1 products have been significantly reduced in price after entering medical insurance.
For example, Cinda Bio's Sintilimab injection entered the 2019 medical insurance through a 63% price reduction, and the annual treatment cost Reduced to less than 100,000 yuan; in the 2020 medical insurance negotiations, BeiGene’s tislelizumab, Junshi Bio’s treprilizumab, and Hengrui Medicine’s carrelizumab are three domestically produced PD- 1 Products are also included in the medical insurance catalog
.
It is reported that after the three products enter the medical insurance, the annual treatment cost may be between 54,000 yuan and 80,000 yuan.
.
Judging from the degree of inclusion of oncology drugs in the previous rounds of medical insurance negotiations, it is expected that Akirensai will also have a good result in this medical insurance negotiation
.
However, some analysts believe that the possibility of Akirensai entering the medical insurance catalog is relatively small, and it is unrealistic for high-value drugs of up to one million to be included in the medical insurance
.
Fosun Kate staff also revealed to the media that the company is actively preparing for negotiations.
It is expected that negotiations will be difficult, but they will try hard
.
In the interpretation of the "Work Plan for Adjusting the National Medical Insurance Drug List in 2021", the National Medical Insurance Administration emphasized: "China is still a developing country, and the financing of basic medical insurance is very limited.
In 2020, the per capita financing of resident medical insurance is only about 800 yuan, of which one-third Second, it also comes from financial subsidies.
Therefore, we must firmly grasp the system positioning of "guarantee basics", focusing on including drugs with high clinical value, reasonable prices, and meeting basic medical needs into the catalog
.
In this year's adjustments, we will continue to strictly grasp Regarding standards and conditions, the society and reporting companies are also requested to maintain reasonable expectations
.
" According to the "Work Plan", if the negotiation goes smoothly, this catalog adjustment will be completed by the end of this year, and we will strive to start implementation in January 2022
.
It remains to be seen what the outcome of the national talks will be
.
